Use of the UniQ® ICTP RIA kit in monitoring bone metastasis of cancer
Bone metastasis of cancer
Osteolytic bone metastases are frequent in patients with advanced cancer of the breast, lung, and (to a lesser extent) the prostate. Roentgenography, bone scintigraphy, and bone biopsies are commonly used for the early identification and follow-up of these conditions. These methods have though marked shortcomings as they are all static methods giving a picture of the current situation in bone but not telling about rate of changes taking place in bone. Metabolic bone markers have been shown to be a useful tool for monitoring metastatic bone activity.
It has been shown that there are two different pathways of bone resorption: the cathepsin K-mediated pathway, which is active during physiological resorption of bone, and the matrix metalloproteinase pathway, which functions mainly in pathological situations. ICTP specifically reflects matrix metalloproteinase-mediated pathological degradation of bone collagen1,2. ICTP is thus a highly specific marker of bone degradation in bone metastasis and constitutes a sensitive and easy means of detecting bone metastases of cancer3-5 and monitoring the response to treatment6.
- Garnero P et al. The type I collagen fragments ICTP and CTX reveal
distinct enzymatic pathways of bone collagen degradation. J Bone Miner
- Sassi ML et al. Immunochemical characterisation
of assay for carboxyterminal telopeptide of human type I collagen: Loss
of antigenicity by treatment with cathepsin K. Bone 2000;26:367-373.
- Leeming D et al. The relative use of eight collagenous and
noncollagenous markers for diagnosis of skeletal metastases in breast,
prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev
- Santala M et al. Comparison of carboxyterminal
telopeptide of type I collagen (ICTP) and CA 125 as predictors of
prognosis in ovarian cancer. Anticanc Res 2004;24:1057-1062.
- Voorzanger-Rousselot N et al. Association of 12 serum biochemical
markers of angiogenesis, tumour invasion and bone turnover with bone
metastases from breast cancer: a crossectional and longitudinal
evaluation. Br J Cancer 2006;95:506-514.
- Lein M et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression. Eur Urol 2007;52:1381-7.
Read more: UniQ ICTP
Published January 4, 2017